SecurityCBIS / Cannabis Science, Inc. (137648101)
President, CEODabney Raymond C.
IndustryCannabis and Medical Marijuana Dispensaries
Institutional Owners14
Institutional Shares299,380 - 0.01%
Common Shares Outstanding22,551,805,296 shares (as of 2017-09-30)
Institutional Value$ 511,000 USD

Institutional Stock Ownership and Shareholders

CBIS / Cannabis Science, Inc. Institutional Ownership

Cannabis Science, Inc. (OTC:CBIS) has 14 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 299,380 shares. Largest shareholders include Donaldson Capital Management, Llc, North Star Asset Management Inc, Providence Wealth Advisors, Llc, Neville Rodie & Shaw Inc, Frontier Investment Mgmt Co, Geneva Advisors, LLC, Edge Wealth Management LLC, Wesbanco Bank Inc, Rothschild Investment Corp /il, and Silvercrest Asset Management Group Llc.
Cannabis Science, Inc. (OTC:CBIS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-13 13F-HR Providence Wealth Advisors, Llc 20,000 20,000 0.00 1 1 0.00
2018-09-04 13F-HR Strategic Wealth Partners, Ltd. 1,200 1,200 0.00 0 0
2018-08-14 13F-HR Stonebridge Capital Advisors LLC 10,000 10,000 0.00 1 1 0.00
2018-08-20 13F-HR MASSMUTUAL TRUST CO FSB/ADV 8,400 8,400 0.00 545 495 -9.17
2018-07-11 13F-HR Gierl Augustine Investment Management Inc 6,000 6,000 0.00 0 0
2018-07-24 13F-HR ROTHSCHILD INVESTMENT CORP /IL 14,000 14,000 0.00 1 1 0.00
2018-08-14 13F-HR SILVERCREST ASSET MANAGEMENT GROUP LLC 10,000 10,000 0.00 1 1 0.00
2018-07-09 13F-HR Fisher Asset Management, LLC 12,000 0 -100.00 1 0 -100.00
2018-07-03 13F-HR NEVILLE RODIE & SHAW INC 20,000 20,000 0.00 1 1 0.00
2018-08-09 13F-HR FRONTIER INVESTMENT MGMT CO 20,000 20,000 0.00 1,298 1 -99.92
2018-08-10 13F-HR NORTH STAR ASSET MANAGEMENT INC 40,000 40,000 0.00 3 2 -33.33
2018-08-08 13F-HR WESBANCO BANK INC 15,000 15,000 0.00 0 0
2018-08-07 13F-HR DONALDSON CAPITAL MANAGEMENT, LLC 99,780 99,780 0.00 6 6 0.00
2017-08-07 13F-HR Geneva Advisors, LLC 20,000 20,000 0.00 2 1 -50.00
2018-07-17 13F-HR Edge Wealth Management LLC 15,000 15,000 0.00 1 1 0.00
CBIS : Cannabis Science Stock Analysis and Research Report

2017-11-23 - Asif

Business Overview Cannabis Science, Inc. (formerly Gulf Onshore, Inc.) (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc. Cannabis Science, Inc. is at the forefront of medical cannabis research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In summary, Cannabis Science is dedicated to the creation of cannabis-based...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

AmeriCann CEO to Present at Science and Education Conference in Massachusetts

2018-09-21 accesswire
DENVER, CO / ACCESSWIRE / September 21, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that CEO Tim Keogh will be speaking at the Cannabis Community Care and Research Network's (C3RN) Cannabis Science and Education Series on Sunday, September 23 in Boston, MA. (2-0)

4 Top Marijuana Penny Stocks for the Rest of 2018

2018-09-06 investorplace
While it’s open to debate whether President Donald Trump made America great, the 2016 election did produce one undeniable result: it laid the foundation for cannabis-related businesses, thereby dramatically improving profitability potential for marijuana penny stocks. (9-3)

Americann Partnership with C3RN Commences Cannabis Research In Massachusetts

2018-07-09 accesswire
DENVER, CO / ACCESSWIRE / July 9, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an agricultural-technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that it is leading a research pilot study in Massachusetts. The research is led by Cannabis Community Care and Research Network (C3RN) in collaboration with UMass Dartmouth. (2-1)

Americann CEO to Present at Science and Education Conference in Massachusetts

2018-06-28 accesswire
DENVER, CO / ACCESSWIRE / June 28, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that CEO Tim Keogh will be speaking at Cannabis Community Care and Research Network's (C3RN) Cannabis Science and Education Series on Thursday, June 28 in Worcester, MA. (9-0)

AmeriCann Partners with C3RN to Conduct Scientific Cannabis Research in Massachusetts

2018-06-20 accesswire
DENVER, CO / ACCESSWIRE / June 20, 2018 / AmeriCann, Inc. (OTCQB: ACAN), an Agricultural-Technology company that is developing the next generation of eco-friendly state-of-the-art greenhouse cannabis cultivation and processing properties, announced today that it is formally partnering with Cannabis Community Care and Research Network (C3RN), a Massachusetts-based public benefit corporation focused on cannabis research and technology. (9-0)

30 Marijuana Stocks to Buy as the Future Turns Green

2018-05-14 investorplace
When it comes to cannabis, we’ve come a long way since former President Bill Clinton denied ever inhaling. With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible. (149-35)

CUSIP: 137648101